New Strategies in Endometrial Cancer: Targeting the PI3K/mTOR Pathway—The Devil Is in the Details

@article{Myers2013NewSI,
  title={New Strategies in Endometrial Cancer: Targeting the PI3K/mTOR Pathway—The Devil Is in the Details},
  author={Andrea Pomrehn Myers},
  journal={Clinical Cancer Research},
  year={2013},
  volume={19},
  pages={5264 - 5274}
}
  • A. Myers
  • Published 1 October 2013
  • Biology
  • Clinical Cancer Research
Endometrial cancer is the most common gynecologic malignancy in the developed world and affects approximately 40,000 women in the United States each year. The phosphoinositide 3-kinase (PI3K) signaling pathway regulates key aspects of cancer biology including glucose uptake and metabolism, cellular growth, and survival. Endometrial cancers harbor the highest rates of PI3K pathway alterations reported to date. The PI3K pathway is highly druggable and several classes of agents are in clinical… 

Figures from this paper

A Review of mTOR Pathway Inhibitors in Gynecologic Cancer
TLDR
The present study reviewed the available evidence regarding the potential impact of some mTOR pathway inhibitors in the treatment of gynecological cancer and concluded that more investigation in PI3K/AKT/mTOR pathway-targeted therapies is warranted.
PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers
TLDR
Evidence is provided that subtherapeutic doses of PI3K inhibitors enhance the efficacy of anti-FGFR therapies, and a combination therapy may represent a superior therapeutic treatment in patients with FGFR2mutant endometrial cancer.
Targeting histone deacetylases in endometrial cancer: a paradigm-shifting therapeutic strategy?
TLDR
The applications of histone deacetylase inhibitors in endometrial cancer appear promising; nonetheless, additional trials are necessary to establish the therapeutic role, clinical utility, and safety of these promising compounds.
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention
TLDR
The targeting of the hormone receptor, HER2 and EGFR1 in breast cancer will be reviewed in association with suppression of the EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway.
YAP1 expression predicts sensitivity to dual AKT/P70S6K inhibition in ovarian and uterine malignancies
TLDR
MSC2363318A decreased tumor growth and metastases in multiple murine orthotopic models of ovarian and uterine cancer and reduced proliferation and angiogenesis indices and increased cell death (cleaved caspase-3) markers.
Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies
TLDR
It is demonstrated that resensitization to bevacizumab occurs with the addition of MSC2363318A, resulting in improved overall survival and support clinical development of a dual AKT/P70S6K inhibitor.
YAP 1 EXPRESSION PREDICTS SENSITIVITY TO DUAL AKT AND P 70 S 6 K INHIBITION IN OVARIAN AND UTERINE MALIGNANCIES By
TLDR
MSC2363318A decreased tumor growth and metastases in multiple murine orthotopic models of ovarian and uterine cancer and reduced proliferation and angiogenesis indices and increased cell death (cleaved caspase-3) markers.
PI3K Pathway Effectors pAKT and FOXO1 as Novel Markers of Endometrioid Intraepithelial Neoplasia
TLDR
This is the first study to demonstrate the potential of pAKT and FOXO1 as biomarkers in the histopathologic evaluation of EIN, and it is shown that variability in expression poses challenges in interpretation.
Recent and current Phase II clinical trials in endometrial cancer: review of the state of art
TLDR
Targeting the phosphoinisotol-3-kinase, angiogenesis, DNA repair and metabolic pathways appear promising strategies for subsets of patients with recurrent or advanced disease and should be explored in the frontline setting.
...
...

References

SHOWING 1-10 OF 66 REFERENCES
The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer
TLDR
Preclinical models are providing insights into the antitumor activity of PI3K/AKT/mTOR pathway inhibition, and are helping define patient populations most likely to benefit from these therapies.
The search continues: Looking for predictive biomarkers for response mTOR inhibition in endometrial cancer.
  • L. Meyer, B. Slomovitz, K. Lu
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
TLDR
Loss of PTEN expression, PS6K expression and KRAS mutational status did not significantly correlate with response to therapy, however, the trend seen in other studies of KRAS as a marker of resistance to mTOR inhibitors such as everolimus was supported by the findings.
The PI3K pathway as drug target in human cancer.
TLDR
This review will discuss how PI3K signaling affects the growth and survival of tumor cells and consider how inhibitors of this pathway, either alone or in combination with other therapeutics, can be used for the treatment of cancer.
Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.
  • A. Oza, L. Elit, E. Eisenhauer
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
PURPOSE Phosphatase and tensin homolog (PTEN) is a tumor suppressor gene, and loss of function mutations are common and appear to be important in the pathogenesis of endometrial carcinomas. Loss of
Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.
  • T. Miller, J. Balko, C. Arteaga
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
TLDR
Altered alterations in the PI3K pathway associated with resistance to endocrine therapy, the state of clinical development ofPI3K inhibitors, and strategies for the clinical investigation of such drugs in hormone receptor-positive breast cancer are reviewed.
Molecular targets and targeted therapeutics in endometrial cancer
TLDR
The clinicopathological and molecular heterogeneity of endometrioid cancer needs to be taken into account in the design of future clinical trials as well as the incorporation of robust biomarkers for the success of therapeutic strategies in endometrial cancer.
Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
TLDR
Everolimus plus letrozole results in a high CBR and RR in patients with recurrent EC, and further development of this combination in recurrent endometrioid EC is under way.
Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study
TLDR
The level of expression of proteins of the PI3K/mTOR pathway tested in this study cannot predict response to everolimus, however, endometrial cancer patients with K-RAS mutations do not seem to derive benefit fromEverolimus treatment.
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.
We demonstrate that phosphatidylinositol 3-kinase (PI3K) pathway aberrations occur in >80% of endometrioid endometrial cancers, with coordinate mutations of multiple PI3K pathway members being more
The PTEN–PI3K pathway: of feedbacks and cross-talks
TLDR
The current status of the PTEN– PI3K signaling pathway is reviewed with special emphasis on the most recent data on targets and regulation of thePTEN–PI3K axis, which provides novel provocative therapeutic implications based on the targeted modulation of PI3k-cross-talking signals.
...
...